GlobeNewswire

Saniona publishes its interim report for the third quarter 2020

Share

PRESS RELEASE

November 30, 2020

Financial highlights

Jan - Sep 2020 (Jan - Sep 2019)

  • Net revenues were SEK 4.6 M (2.7 M)
  • EBIT was SEK -97.0 M (-75.8 M)
  • Net profit/loss was SEK -117.3 M (-72.3 M)
  • Earnings per share were SEK -3.47 (-2.89)
  • Diluted earnings per share were SEK -3.47 (-2.89)

Q3 2020 (Q3 2019)

  • Net revenues were SEK 2.2 M (0.3 M)
  • EBIT was SEK -40.9 M (-26.0 M)
  • Net profit/loss was SEK -52.7 M (-27.7 M)
  • Earnings per share were SEK -1.24 (-1.00)
  • Diluted earnings per share were SEK -1.24 (-1.00)

Business highlights in Q3 2020

  • On August 10, 2020, Saniona announced the direct issue of shares raising USD $65 million (approximately SEK 567 million) with a syndicate of U.S. and international institutional investors and sector specialists. The Directed Issue was led by RA Capital Management with participation from Pontifax Venture Capital, New Leaf Venture Partners, and other U.S. and international investors including the Second Swedish National Pension Fund (AP2), the Third Swedish National Pension Fund (AP3) and the Fourth Swedish National Pension Fund (AP4).
  • On August 26, 2020, Saniona announced the expansion of its executive team with the appointments of Jason A. Amello as Chief Financial Officer, Trista Morrison as Chief Communications Officer, and Linea Aspesi as Chief Human Resources Officer.
  • On September 23, 2020, Saniona completed the exercise of warrants of series TO2, which were issued in connection with Saniona’s rights issue and directed issue in the first quarter of 2020. In total, 1,329,141 warrants of series TO2 were exercised, corresponding to a subscription rate of approx. 90 percent. Saniona will thereby receive proceeds of SEK 33.2 million (USD 3.6 million), before issue costs, which amount to approx. SEK 0.4 million.

Significant events after the reporting period

  • On October 9, 2020, Saniona announced that it received written feedback from the U.S. Food and Drug Administration (FDA) regarding pre-Investigational New Drug (IND) submissions for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO). In both indications, the FDA recommended that the clinical development program include a supportive Phase 2b study followed by a Phase 3 study. In PWS, Saniona expects to begin the Phase 2b study in the first half of 2021. In HO, Saniona is working on a plan, which it intends to present to the FDA to ensure that should Tesomet receive regulatory approval for HO, its use would be restricted only to the appropriate patients. Once this is addressed, Saniona anticipates beginning the HO Phase 2b study in the first half of 2021.
  • On November 9, 2020, Saniona announced that it had refined its pipeline to align its early-stage discovery research with its strategic focus on rare diseases. Saniona regained exclusive, global rights to its GABAa5 negative allosteric modulator program (“GABAa5 program”) from Boehringer Ingelheim, which terminated this collaboration for strategic reasons. The termination of the collaboration provided Saniona with rights to a portfolio of more than 800 molecules, and it does not impact the 2020 collaboration between Saniona and Boehringer Ingelheim, which remains ongoing. Separately, Saniona and the Treatment Research Center (TRC) at the University of Pennsylvania jointly discontinued their collaboration to develop NS2359 for cocaine addiction. Saniona will evaluate the applicability of the GABAa5 program assets and NS2359 in rare diseases.
  • On November 23, 2020, Saniona announced positive top-line results from the Phase 2 open-label extension study of Tesomet in patients with hypothalamic obesity (HO). Patients treated with Tesomet for nearly one year (24 week double-blind [DB] followed by 24 week open label extension [OLE]) demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference, as well as improvements in glycemic control. Tesomet was well tolerated, and no clinically meaningful differences in heart rate or blood pressure were observed over the course of the trial.


"In the third quarter, we continued to transform Saniona into a fully-integrated biopharmaceutical company with the ability to discover, develop and ultimately commercialize our own innovative treatments for rare diseases. We were particularly encouraged by the positive data from the Phase 2 open-label extension study of Tesomet in HO, which we intend to discuss with FDA as we clarify the path forward in this rare indication,” said Rami Levin, President & Chief Executive Officer of Saniona. “During the quarter, one of our most important achievements was raising USD $65 million, which coupled with our existing cash resources, will fund our current operating plan into the second half of 2022, as originally planned. We believe access to U.S. patients, physicians and the U.S. financial market are critical for Saniona to unlock its long-term potential, and as such we are continuing to build our U.S. team and considering listing our shares on the U.S. Nasdaq exchange in addition to our existing listing on Nasdaq Stockholm.”

There are multiple potential advantages to a dual listing, including increased visibility and access to a greater number of potential investors, as well as potential increased liquidity (trading volume) from different markets with different macroeconomic conditions, allowing investors to purchase and sell shares on either exchange.

For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com

This information is such information as Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 CET on November 30, 2020.

About Saniona
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona intends to develop and commercialize its rare disease products internally. The company has out-licensed other programs, which may provide future supplemental revenue. Saniona is based in Copenhagen, Denmark and Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Corr: SpareBank 1 SMN: Presentation of 4th Quarter 2020 accounts22.1.2021 13:23:24 CETPress release

SpareBank 1 SMN is presenting 4th quarter 2020 financial results. Time: Friday 5 February at 08:00 AM CET Place: Webinar Please register by 4 February on the link below: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 The presentation will be held in Norwegian by group CEO Jan-Frode Janson and CFO Kjell Fordal. We will also host a Global Investor Webinar in English on the same day at 3:15 PM CET. Please register by 4 February on the following link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Questions to the management in relation to both presentations can be sent to ir@smn.no. The results will be published on 5 February at 7:00 AM CET. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Korr: SpareBank 1 SMN: Invitasjon til resultatpresentasjon, 4. kvartal 202022.1.2021 13:23:24 CETPressemelding

SpareBank 1 SMN inviterer til presentasjon av resultatene for 4. kvartal 2020. Tid: Fredag, 5. februar, kl. 08:00 Sted: Webinar Påmelding innen 4. februar via følgende link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 Presentasjonen holdes av konsernsjef Jan-Frode Janson og finansdirektør Kjell Fordal. Det vil også bli holdt et webinar på engelsk samme dag klokken 15:15. Påmelding til den engelske presentasjonen innen 4. februar kan gjøres her: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Spørsmål til begge presentasjoner kan sendes til ir@smn.no. Resultatet publiseres 5. februar klokken 07:00 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

PCI Biotech to present at RNA Therapeutics Virtual Conference22.1.2021 12:04:15 CETPress release

Oslo (Norway), 22 January 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that it will present at the 12th Annual RNA Therapeutics Virtual Conference, a UK based online event taking place February 10-11, 2021. The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations. PCI Biotech is also a sponsor of the event. On Wednesday, February 10, 2021 at 13:10pm (CET), Dr. Anders Høgset, CSO, will present an overview of PCI Biotech’s proprietary platform technology, focusing on the delivery of RNA molecules, including the most recent data on the use of the fimaNAc delivery technology in the exciting field of RNA based therapies. The presentation slides will be made available t

SpareBank 1 SMN: Invitasjon til resultatpresentasjon, 4. kvartal 202022.1.2021 10:47:43 CETPressemelding

SpareBank 1 SMN inviterer til presentasjon av resultatene for 4. kvartal 2020. Tid: Fredag, 5. februar, kl. 08:00 Sted: Webinar Påmelding innen 4. februar via følgende link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 Presentasjonen holdes av konsernsjef Jan-Frode Janson og finansdirektør Kjell Fordal. Det vil også bli holdt et webinar på engelsk samme dag klokken 15:15. Påmelding til den engelske presentasjonen innen 4. februar kan gjøres her: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Spørsmål til begge presentasjoner kan sendes til ir@smn.no. Resultatet publiseres 5. februar klokken 07:00 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

SpareBank 1 SMN: Presentation of 4th Quarter 2020 accounts22.1.2021 10:47:43 CETPress release

SpareBank 1 SMN is presenting 4th quarter 2020 financial results. Time: Friday 5 February at 08:00 AM CET Place: Webinar Please register by 4 February on the link below: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 The presentation will be held in Norwegian by group CEO Jan-Frode Janson and CFO Kjell Fordal. We will also host a Global Investor Webinar in English on the same day at 3:15 PM CET. Please register by 4 February on the following link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Questions to the management in relation to both presentations can be sent to ir@smn.no. The results will be published on 5 February at 7:00 AM CET. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS22.1.2021 10:07:00 CETPress release

Auction date2021-01-22Loan3111Coupon0.125 %ISIN-codeSE0007045745Maturity2032-06-01Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,674Volume bought, SEK mln500Number of bids14Number of accepted bids6Average yield-1.592Lowest accepted yield-1.598Highest yield-1.585% accepted at lowest yield 33.33 Auction date2021-01-22Loan3112Coupon0.125 %ISIN-codeSE0008014062Maturity2026-06-01Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,450Volume bought, SEK mln500Number of bids10Number of accepted bids3Average yield-1.727Lowest accepted yield-1.731Highest yield-1.719% accepted at lowest yield 100.00